Table 2.
Characteristic | Paricalcitol | Cinacalcet | p valuea |
---|---|---|---|
Subjects [n] | 51 | 47 | |
Age [years; mean ± SD] | 61.0 ± 11.5 | 60.7 ± 11.6 | 0.8984 |
Male [n (%)] | 31 (60.8) | 28 (59.6) | 0.9027 |
Race [n (%)] | 0.3147 | ||
White | 24 (47.1) | 26 (55.3) | |
Black | 25 (49.0) | 19 (40.4) | |
Other | 2 (4.0) | 2 (4.3) | |
Hispanic [n (%)] | 11 (21.6) | 13 (27.7) | 0.4836 |
Diabetes [n (%)] | |||
Type 1 | 5 (9.8) | 1 (2.1) | 0.1133 |
Type 2 | 33 (64.7) | 26 (55.3) | 0.3429 |
Cardiovascular disease [n (%)] | |||
Angina | 7 (13.7) | 1 (2.1) | 0.0362 |
Myocardial infarction | 10 (19.6) | 4 (8.5) | 0.1168 |
Coronary artery disease | 20 (39.2) | 13 (27.7) | 0.2265 |
Left ventricular hypertrophy | 11 (21.6) | 2 (4.3) | 0.0116 |
Duration of dialysis [years; mean ± SD] | 3.9 ± 3.3 | 3.9 ± 3.3 | 0.9948 |
Blood pressure [mmHg; mean ± SD] | |||
Systolic | 142.8 ± 26.1 | 149.4 ± 24.7 | 0.2016 |
Diastolic | 72.7 ± 12.9 | 76.5 ± 15.2 | 0.1839 |
Concomitant medications [n (%)] | |||
Angiotensin-converting enzyme inhibitors | 20 (39.2) | 18 (38.3) | 0.9258 |
Angiotensin II receptor blockers | 9 (17.6) | 7 (14.9) | 0.7126 |
Beta blockers | 35 (68.6) | 27 (57.4) | 0.2514 |
Calcium channel blockers | 26 (51.0) | 24 (51.1) | 0.9934 |
Diuretics | 16 (31.4) | 9 (19.1) | 0.1655 |
Erythropoiesis-stimulating agents | 43 (84.3) | 38 (80.8) | 0.6511 |
Baseline laboratory values | |||
Serum iPTH level [pg/mL; mean ± SD] | 516.6 ± 147.9 | 524.3 ± 149.7 | 0.7984 |
Corrected calcium level [mg/dL; mean ± SD] | 9.0 ± 0.5 | 9.1 ± 0.4 | 0.5402 |
Phosphorus level [mg/dL; mean ± SD] | 4.8 ± 1.0 | 5.0 ± 1.0 | 0.4789 |
Alkaline phosphatase level [IU/L; mean ± SD] | 111.9 ± 52.8 | 126.9 ± 52.4 | 0.1617 |
Bone-specific alkaline phosphatase level [U/L; mean ± SD] | 35.7 ± 15.8 | 41.7 ± 26.7 | 0.1801 |
25-hydroxy vitamin D level [ng/mL; mean ± SD]b | 23.0 ± 14.0 | 23.7 ± 9.7 | 0.8148 |
Creatinine level [mg/dL; mean ± SD]c | 8.1 ± 2.3 | 9.0 ± 2.5 | 0.0994 |
Albumin level [g/dL; mean ± SD] | 4.0 ± 0.2 | 4.0 ± 0.3 | 0.6989 |
iPTH intact parathyroid hormone, SD standard deviation
aDifferences between groups were considered statistically significant (indicated by bold text) if p < 0.05 on the basis of Pearson’s chi-squared test or Student’s t test
bNot all subjects had a baseline value recorded for this item—n = 36 in the paricalcitol group and n = 36 in the cinacalcet group
cNot all subjects had a baseline value recorded for this item—n = 46 in the paricalcitol group and n = 50 in the cinacalcet group